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Abstract
With survival after retransplant improving over the
years, issues regarding multiple retransplant have
emerged. Here, we report the 25-year follow-up of a
16-year-old male patient who received 4 successful
lung transplant procedures in 1990, 1991, 1995, and
2005.
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Introduction
The main long-term complication after lung trans -
plant is chronic graft dysfunction. Lung retransplant
is presently the only curative strategy in the
management of chronic rejection, provided that the
patient appears fit for this procedure. With the
growing volume of primary lung transplants, the
demand for lung retransplant has also become
increasingly common over the past decade.1-3 The
main indications for lung retransplant include airway
complications, acute graft failure, and chronic graft
dysfunction. However, lung retransplant for acute
graft failure and early airway complications have
dramatically decreased during the past decade
because of poor reported outcomes. In contrast, lung
retransplant for chronic allograft dysfunction has
continued as survival rates approach those obtained
after first lung transplant. Several studies have shown
that long-term survival rates after lung retransplant
for chronic rejection have approached the survival
rates of primary lung transplant. As survival after
retransplant becomes more prolonged, complications
after multiple lung retransplants emerge.
Here, we present a 25-year follow-up of a male
patient with cystic fibrosis who underwent a total of 4
successive lung transplant procedures in 1990, 1991,
1995, and 2005. To our knowledge, this is one of the
first cases of reported multiple lung retransp lants.
Case Report
The study patient was diagnosed with cystic fibrosis at
6 years old. He was admitted to the intensive care unit
with end-stage disease at age 16 years and was put on
the wait list for lung transplant. After 22 days with
artificial ventilation through a tracheotomy, suitable
donor lungs became available and he underwent a
bilateral lung transplant according to the en bloc
technique with bilateral bronchial anastomoses. The
procedure, performed in March 1990, showed an
initially favorable clinical outcome. However, several
months after transplant, lung function had dete -
riorated. Biopsy findings confirmed acute rejection.
After failure of steroid bolus therapy, muromonab-
CD3 (OKT3, Johnson & Johnson, Highland Park, NJ,
USA) was administered without further success. The
patient was transferred to the intensive care unit and
put under artificial ventilation. Because there was an
irreversible alteration of graft function, he was again
placed on the emergency transplant list.
In January 1991, after 63 days of artificial ven -
tilation, a heart-lung transplant was performed. His
respiratory function gradually improved until 1993,
when a pulmonary biopsy showed grade 1 rejection
associated with hemosiderosis.
In September 1995, he received a left lung trans -
plant without cardiopulmonary bypass, which
resulted in a satisfactory outcome posttransplant. 
He was kept on the standard immunosuppressive 
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regi men of the mid-1990s (combined methylpre -
dnisolone, cyclosporine, and azathioprine). In March
2004, the patient’s situation again started to deteriorate.
Chest computed tomography scan findings were
suggestive of right-sided constrictive bronchiolitis and
left-sided bronchiolitis obliterans. Bronchoalveolar
lavage revealed infection with methicillin-resistant
coagulase-negative Staphylococcus species. Despite
treatment with vancomycin and pristinamycin,
respiratory function deterioration progressed
relentlessly.
In October 2005, the patient underwent right lung
retransplant without extracorporeal circulation, with
extubation 2 days after surgery. One month later, the
patient was hospitalized for infectious bronchitis.
Biology revealed coagulase-negative Staphylococcus
and Enterococcus infections, which were sensitive 
to amoxicillin. The patient responded well to the
antibiotics and was discharged.
In January 2006, the patient presented with pro -
ductive cough with sputum. Microbiologic test
showed relapsing Enterococcus and Staphylococcus
infections. An acute transplant rejection due to
superinfection was suspected, and treatment with
antilymphocyte antibody (OKT3) was provided. The
next 7 years were uneventful. However, in October
2013, the patient had a splenectomy for spontaneous
rupture of the spleen, leading to the discovery of a
posttransplant Epstein-Barr virus-related lymphoma.
The latter responded well to 4 cycles of R-CHOP
(cyclophosphamide, doxorubicin, vincristine, pred -
nisone, plus rituximab). In March 2014, the patient
presented with relapse of Epstein-Barr virus
lymphoma. After 4 shots of rituximab, second-line
chemotherapy with ifosfamide-etoposide and ofatu -
mumab was started. Although the patient had a
partial response after the first 2 cycles, performance
status declined to a World Health Organization 3/4
category. The 3rd and 4th cycles of treatment were
poorly tolerated. After several episodes of septic
shock, the patient ultimately died in July 2014.
Discussion
With survival of retransplant improving over the
years, issues with regard to multiple retransplants
have emerged. Lung retransplant comprises an
increasing share of lung transplants, and recently
patients have shown improved outcomes. The
median survival of patients who undergo lung
retransplant has been shown to be 2 years.2 Median
survival after lung retransplant for bronchiolitis
obliterans syndrome is longer than survival after
retransplant for restrictive chronic lung allograft
dysfunction. In a study from Thomas and colleagues,
1-year survival was only 50% after lung retransplant
for acute graft failure and airway complications;
however, lung retransplant for bronchiolitis obli -
terans syndrome showed superior survival at 1 year
(78%) and at 5 years (62%). These latter rates are
similar to survival rates for first-time lung transplant
recipients. The authors concluded that lung retrans -
plant may be appropriate in well-selected patients
with chronic lung allograft failure.3
Presently, there are no reports about outcomes 
of multiple lung retransplant procedures. There 
are many unanswered questions regarding ethics,
indication, immunology, and graft tolerance, 
management of immunosuppression, and long-term
outcomes. Our reported case demonstrates that
prolonged survival is possible: this particular patient
underwent 4 transplants over a 25-year period. Two
of these transplants were followed by survival of
almost 10 years each.
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